Nature Medicine· Karen O’Leary·· 23 小时前AI 评分58
阿尔茨海默病小分子 TREM2 激动剂 VG-3927 的临床前分析与 Phase 1 结果
A small-molecule TREM2 agonist for Alzheimer’s disease
AI 导读
Nature Medicine 报道，临床前分析与一项 Phase 1 试验支持将 VG-3927 作为阿尔茨海默病的候选药物，结果显示其可穿透中枢神经系统、实现靶点结合并具备耐受性。
正文 · 原文
Nature Medicine, Published online: 29 October 2026; doi:10.1038/d41591-026-00055-x
Preclinical analysis and a phase 1 trial support VG-3927 as a promising drug candidate for Alzheimer’s disease, demonstrating successful penetration of the central nervous system, target engagement and tolerability.
来源：Nature Medicine · nature.com